Furthermore, it is still unclear why PHLDA2 expression affects the therapeutic effect of ICI plus anti-angiogenic agent in ccRCC, and further studies are required to explore potential treatment strategies for ccRCC patients with higher PHLDA2 expression. The gene discussed is PHLDA2; the disease is nonpapillary renal cell carcinoma.